The first domestic insurance benefit for an oral hepatitis C treatment with the ‘shocking’ drug price
An oral hepatitis C treatment will acquire the health insurance benefit for the first time in Korea. The subject of the news is the BMS’s dual therapy of ‘Daklinza(generic name: daclatasvir)’ and ‘Sunvepra(asunaprevir).’
According to a person concerned of the benefit policy, the BMS’s dual thera...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
